The warrants would remain and are basically option calls with a more complicated execution mechanism. They too should be close to share price with either a small premium or perhaps a discount based on investor sentiment.
My outlook is that all of these intertwined symbols, RLFTF/ACER & NRX/BRPA(U/W/R) plays are all going to do very well. Picking which one at the right time would involve some luck, so I own them all personally. They all offer rocket ship potential.
Here's a scenario: You believe a developer is going to plan to build a office building on a certain block in NYC. There are several smaller buildings/parcels on that block currently for sale on the market. One is listed at 1.5m, one at 2.0m, and another at 2.5m. You believe they are currently undervalued already and that you will be able to get exponentially more once the mega office building plans are announced by the developer. Which one do you buy so you make money?
In this scenario, each would make you money and you would do well. Choosing which is trivial since they all would offer the same exponential gains. As for me, I would buy all of the properties...
Best,
JB
Disclaimer
All of my posts are just my own opinion and not advice to buy, sell or trade any stock, security or anything else for that matter. I post my own personal thoughts and information that I have found regarding positions that I am invested in.
Recent NRXP News
- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Participate in the EF Hutton Annual Global Conference on May 15, 2024 • PR Newswire (US) • 05/08/2024 12:30:00 PM
- NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) to Report First Quarter 2024 Financial Results on May 14, 2024 • PR Newswire (US) • 05/07/2024 08:01:00 PM
- NRx Pharmaceuticals (Nasdaq:NRXP) Announces Final Clinical Trial Results: Superior Safety Combined with Similar Efficacy in the Trial of NRX-101 Compared to Lurasidone in Suicidal Bipolar Depression • PR Newswire (US) • 05/06/2024 12:30:00 PM
- NRx Pharmaceuticals (Nasdaq:NRXP) Announces Promising Findings in Phase 2b/3 Clinical Trial of NRX-101 vs. Lurasidone for Treatment of Suicidal Bipolar Depression • PR Newswire (US) • 04/30/2024 12:30:00 PM
- NRx Pharmaceuticals (NASDAQ:NRXP) Receives Notice from Nasdaq that the Company has Demonstrated Compliance with the Bid Price Requirement • PR Newswire (US) • 04/18/2024 12:32:00 PM
- NRx Pharmaceuticals, Inc. Announces Pricing of $2.0 Million Underwritten Public Offering of Common Stock • PR Newswire (US) • 04/18/2024 12:30:00 PM
- NRx Pharmaceuticals, Inc. Announces Proposed Underwritten Public Offering of Common Stock • PR Newswire (US) • 04/17/2024 08:45:00 PM
- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces New Data on NRX-101 Demonstrating No Damage to Intestinal and Vaginal Flora in Validated Rodent Models Compared to Standard Antibiotics: Potential Implications for Avoidance of C. Difficile infections • PR Newswire (US) • 04/17/2024 12:30:00 PM
- NRx Pharmaceuticals (NASDAQ:NRXP) Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine) • PR Newswire (US) • 04/15/2024 12:30:00 PM
- NRx Pharmaceuticals (NASDAQ:NRXP) Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression • PR Newswire (US) • 04/08/2024 12:30:00 PM
- NRx Pharmaceuticals (Nasdaq:NRXP) Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • PR Newswire (US) • 04/01/2024 12:28:00 PM
- NRx Pharmaceuticals (NASDAQ:NRXP) Reports Preliminary Fourth Quarter and Full Year 2023 Financial Results and Provides Year End Highlights • PR Newswire (US) • 03/28/2024 12:03:00 PM
- NRx Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing • PR Newswire (US) • 03/28/2024 12:00:00 PM
- NRx Pharmaceuticals (NASDAQ: NRXP) to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024 • PR Newswire (US) • 03/26/2024 08:03:00 PM
- NRx Pharmaceutical's (NASDAQ:NRXP) Chairman Dr. Jonathan Javitt to Present at the Ketamine 2024 Conference in Oxford, UK • PR Newswire (US) • 03/25/2024 12:30:00 PM
- NRx Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Corporate Update on March 28, 2024 • PR Newswire (US) • 03/21/2024 08:02:00 PM
- NRx Pharmaceuticals Announces Results of the Vote Held During the Special Meeting of Shareholders • PR Newswire (US) • 03/21/2024 05:57:00 PM
- NRx Pharmaceuticals (NASDAQ:NRXP) Initiates Strategy to Combat Short Sales • PR Newswire (US) • 03/12/2024 11:49:00 AM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/11/2024 09:16:06 PM
- NRx Pharmaceuticals (NASDAQ:NRXP) Completes Memorandum of Understanding and Collaborations with Distribution Partners for HTX-100 (IV Ketamine) • PR Newswire (US) • 03/11/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 09:08:01 PM
- NRx Pharmaceuticals (NASDAQ: NRXP) Announces Last Patient, Last Visit in its Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression • PR Newswire (US) • 03/04/2024 01:30:00 PM
- NRx Pharmaceuticals Announces Definitive Purchase Agreement for Common, Unregistered Shares at $0.38 per Share • PR Newswire (US) • 03/01/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 10:09:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/28/2024 03:40:51 PM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM